These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 21617879)

  • 1. Prognostic implications of the DNA damage response pathway in glioblastoma.
    Seol HJ; Yoo HY; Jin J; Joo KM; Kong DS; Yoon SJ; Yang H; Kang W; Lim DH; Park K; Kim JH; Lee JI; Nam DH
    Oncol Rep; 2011 Aug; 26(2):423-30. PubMed ID: 21617879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.
    Bartkova J; Hamerlik P; Stockhausen MT; Ehrmann J; Hlobilkova A; Laursen H; Kalita O; Kolar Z; Poulsen HS; Broholm H; Lukas J; Bartek J
    Oncogene; 2010 Sep; 29(36):5095-102. PubMed ID: 20581868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
    Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
    Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray.
    Yin D; Ogawa S; Kawamata N; Tunici P; Finocchiaro G; Eoli M; Ruckert C; Huynh T; Liu G; Kato M; Sanada M; Jauch A; Dugas M; Black KL; Koeffler HP
    Mol Cancer Res; 2009 May; 7(5):665-77. PubMed ID: 19435819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of DNA damage response in intracranial germ cell tumors versus glioblastomas reflect cell of origin rather than brain environment: implications for the anti-tumor barrier concept and treatment.
    Bartkova J; Hoei-Hansen CE; Krizova K; Hamerlik P; Skakkebæk NE; Rajpert-De Meyts E; Bartek J
    Mol Oncol; 2014 Dec; 8(8):1667-78. PubMed ID: 25066726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Grade-specific expression of insulin-like growth factor-binding proteins-2, -3, and -5 in astrocytomas: IGFBP-3 emerges as a strong predictor of survival in patients with newly diagnosed glioblastoma.
    Santosh V; Arivazhagan A; Sreekanthreddy P; Srinivasan H; Thota B; Srividya MR; Vrinda M; Sridevi S; Shailaja BC; Samuel C; Prasanna KV; Thennarasu K; Balasubramaniam A; Chandramouli BA; Hegde AS; Somasundaram K; Kondaiah P; Rao MR
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1399-408. PubMed ID: 20501753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel glioblastoma markers with diagnostic and prognostic value identified through transcriptome analysis.
    Reddy SP; Britto R; Vinnakota K; Aparna H; Sreepathi HK; Thota B; Kumari A; Shilpa BM; Vrinda M; Umesh S; Samuel C; Shetty M; Tandon A; Pandey P; Hegde S; Hegde AS; Balasubramaniam A; Chandramouli BA; Santosh V; Kondaiah P; Somasundaram K; Rao MR
    Clin Cancer Res; 2008 May; 14(10):2978-87. PubMed ID: 18483363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
    Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
    Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of p53 and p21 in primary glioblastomas.
    Gross MW; Kraus A; Nashwan K; Mennel HD; Engenhart-Cabillic R; Schlegel J
    Strahlenther Onkol; 2005 Mar; 181(3):164-71. PubMed ID: 15756520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance.
    Squatrito M; Holland EC
    Cancer Res; 2011 Sep; 71(18):5945-9. PubMed ID: 21917735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme.
    Ruano Y; Mollejo M; Camacho FI; Rodríguez de Lope A; Fiaño C; Ribalta T; Martínez P; Hernández-Moneo JL; Meléndez B
    Cancer; 2008 Apr; 112(7):1575-84. PubMed ID: 18260157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.
    Nakagawa T; Ido K; Sakuma T; Takeuchi H; Sato K; Kubota T
    Neuropathology; 2009 Aug; 29(4):379-88. PubMed ID: 19019175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients.
    Wang LF; Fokas E; Bieker M; Rose F; Rexin P; Zhu Y; Pagenstecher A; Engenhart-Cabillic R; An HX
    Oncol Rep; 2008 Jan; 19(1):151-6. PubMed ID: 18097589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The DNA methylome of glioblastoma multiforme.
    Martinez R; Esteller M
    Neurobiol Dis; 2010 Jul; 39(1):40-6. PubMed ID: 20064612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors.
    Faury D; Nantel A; Dunn SE; Guiot MC; Haque T; Hauser P; Garami M; Bognár L; Hanzély Z; Liberski PP; Lopez-Aguilar E; Valera ET; Tone LG; Carret AS; Del Maestro RF; Gleave M; Montes JL; Pietsch T; Albrecht S; Jabado N
    J Clin Oncol; 2007 Apr; 25(10):1196-208. PubMed ID: 17401009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
    Shinojima N; Tada K; Shiraishi S; Kamiryo T; Kochi M; Nakamura H; Makino K; Saya H; Hirano H; Kuratsu J; Oka K; Ishimaru Y; Ushio Y
    Cancer Res; 2003 Oct; 63(20):6962-70. PubMed ID: 14583498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated ERK1/2 expression in glioblastoma multiforme and in peritumor tissue.
    Lama G; Mangiola A; Anile C; Sabatino G; De Bonis P; Lauriola L; Giannitelli C; La Torre G; Jhanwar-Uniyal M; Sica G; Maira G
    Int J Oncol; 2007 Jun; 30(6):1333-42. PubMed ID: 17487353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme.
    Liu W; Fu Y; Xu S; Ding F; Zhao G; Zhang K; Du C; Pang B; Pang Q
    J Clin Neurosci; 2011 Jan; 18(1):119-21. PubMed ID: 20832323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diversity of cytogenetic and pathohistologic profiles in glioblastoma.
    Hassler M; Seidl S; Fazeny-Doerner B; Preusser M; Hainfellner J; Rössler K; Prayer D; Marosi C
    Cancer Genet Cytogenet; 2006 Apr; 166(1):46-55. PubMed ID: 16616111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.